MR-proADM: A Peptide Biomarker That Predicts Organ Failure Better Than Standard Tests | Research

The takeaway

Mid-regional pro-adrenomedullin outperforms procalcitonin and CRP for predicting organ failure and death in sepsis, reflecting severity rather than infection type.

Organ failure marker
MR-proADM predicts organ failure severity and mortality independent of the infecting pathogen — measuring how badly the body is failing, not what's causing the infection

What the researchers found

Mid-regional pro-adrenomedullin (MR-proADM) — a stable surrogate marker for the peptide hormone adrenomedullin — is emerging as a superior biomarker for organ failure and mortality risk in sepsis patients. MR-proADM outperformed both procalcitonin (PCT) and C-reactive protein (CRP) for predicting unfavorable outcomes and death in ICU patients with sepsis.

Importantly, MR-proADM levels are independent of the infecting organism — instead, they reflect the magnitude of organ failure itself, making it a severity marker rather than an infection marker. Serial MR-proADM measurements on days 2–5 of ICU admission help identify patients with poor prognosis. The review recommends adding MR-proADM to the standard biomarker panel for critically ill sepsis patients.

Why it matters

Sepsis kills more people than heart attacks and is notoriously difficult to diagnose and monitor. Current biomarkers like procalcitonin tell you about infection but not about organ failure — which is what actually kills sepsis patients. MR-proADM fills this gap by measuring the body's vasodilatory stress response, which directly reflects how badly organs are failing. Combining PCT (infection marker) with MR-proADM (organ failure marker) could give ICU doctors a much clearer picture of disease severity and guide treatment decisions.

The numbers in context

MR-proADM > PCT > CRP for mortality prediction · organ failure severity independent of pathogen · serial levels days 2–5 most informative · ADM produced by bone, adrenal, kidney, lung, vessels, heart

How the study worked

Narrative review synthesizing evidence from clinical studies on MR-proADM as a biomarker in sepsis and critical illness, comparing its prognostic performance to procalcitonin and CRP across emergency department and ICU settings.

Who was studied

Not applicable (review of clinical biomarker studies in sepsis and critically ill ICU patients)

What this study cannot tell us

Narrative review without systematic search methodology. MR-proADM is not yet universally available in clinical laboratories. Optimal cutoff values for clinical decision-making are not standardized. Most supporting evidence comes from observational studies rather than interventional trials that show outcomes improve when MR-proADM guides treatment. The review focuses primarily on sepsis and may overstate generalizability to other critical illnesses.

How to read the evidence

This is a narrative review synthesizing clinical biomarker data from multiple ICU studies. The 'Moderate' grade reflects the clinical evidence supporting MR-proADM's prognostic superiority, while acknowledging the review format and the lack of large interventional trials.

When this study was published

Published in 2016, this review captured the growing evidence for MR-proADM in sepsis. Since then, additional studies have further supported its use, and MR-proADM has been incorporated into some European sepsis management protocols.

The bigger picture

Adrenomedullin is one of the most potent vasodilating peptides in the body — it relaxes blood vessels, has cardiac-protective effects, and modulates the immune response. In sepsis, massively elevated adrenomedullin drives the dangerous drop in blood pressure that causes organ failure. Measuring its stable proxy (MR-proADM) gives clinicians a direct window into this pathological process. A new antibody-based therapy targeting adrenomedullin (adrecizumab) is being developed for sepsis treatment, making MR-proADM relevant as both a diagnostic and a companion biomarker.

Questions still open

Can MR-proADM-guided treatment protocols improve survival in sepsis compared to standard biomarker panels?
What are the optimal MR-proADM cutoff values for clinical decision-making in the ICU?
Could targeting adrenomedullin directly (with antibodies) improve outcomes in patients with high MR-proADM levels?

Common questions

What is adrenomedullin and why do its levels rise in sepsis?

Adrenomedullin is a peptide hormone produced by many tissues that powerfully relaxes blood vessels and has anti-inflammatory effects. In sepsis, the body massively ramps up adrenomedullin production in response to the inflammatory storm — but this overproduction actually makes things worse by causing dangerous drops in blood pressure and contributing to organ failure. MR-proADM is a stable fragment that's released in equal amounts, making it easy to measure in the blood.

Why is MR-proADM better than procalcitonin for predicting death in sepsis?

Procalcitonin tells you about the presence and severity of bacterial infection, but sepsis kills through organ failure — and infection severity doesn't always correlate with organ damage. MR-proADM directly reflects the vascular dysfunction and organ failure that actually drives mortality. A patient might have moderate infection markers but severe organ failure (high MR-proADM), which procalcitonin alone would miss.

Read the original research

New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.

Annals of translational medicine, 4(17), 329

View on PubMed ↗

Citation

Valenzuela-Sánchez, Francisco; Valenzuela-Méndez, Blanca; Rodríguez-Gutiérrez, Juan Francisco; Estella-García, Ángel; González-García, María Ángela. (2016). New role of biomarkers: mid-regional pro-adrenomedullin, the biomarker of organ failure.. Annals of translational medicine, 4(17), 329.